RSV Trends After COVID-19: Back With a Vengeance Medscape InDiscussion: Respiratory Syncytial Virus in Adults

Join Drs Forest Arnold and Victoria Statler as they discuss RSV after the COVID-19 pandemic. Tune in to hear about an increase in hospitalization rates, surprising seasonal shifts, and more.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/985977). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
CDC RSV National Trends https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html
RSV-NET https://www.cdc.gov/rsv/research/rsv-net/overview-methods.html
Palivizumab for the Prevention of Respiratory Syncytial Virus Infection https://pubmed.ncbi.nlm.nih.gov/20705882/
Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins https://pubmed.ncbi.nlm.nih.gov/24362685/
Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022-2023 RSV Season https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/
Type and Duration of Precautions Recommended for Selected Infections and Conditions https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/type-duration-precautions.html